Source-grounded facts extracted from Cytek Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Philippe Busque resigned as Senior Vice President, Global Sales and Services at Cytek Biosciences, Inc..
“On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.”
Cytek Biosciences, Inc. reported first quarter ended March 31, 2026 results: revenue $44.1 million, net income Net loss in the first quarter of 2026 was $18.9 million. Guidance reaffirmed.
“cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Total revenue for the first quarter of 2026 was $44.1 million, representing a 6% increase compared to the first quarter of 2025 • Service revenue for the first quarter of 2026 was $15.4 million, representing a 15% increase compared to”
Paul Christopher Williams resigned as Chief Operating Officer at Cytek Biosciences, Inc..
“On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.”
Cytek Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $44.9 million, net income $6.2 million. Guidance reaffirmed.
“(Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023 •”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.